MABWELL-B Shares Surge Over 23% to Record High in Early Trading, Four Products Approved for Market

Deep News04-30

MABWELL-B (02493) saw its shares rise more than 23% during early trading, reaching a peak of HK$31.46, marking a new record high since its listing. At the time of writing, the stock was up 7.22% to HK$27.32, with a turnover of HK$184 million.

On April 28, MABWELL-B officially began trading on the main board of the Hong Kong Stock Exchange and was included in the Stock Connect scheme on its first day, becoming the first A-to-H share company listed under Chapter 18A. Since its establishment, the company has successfully advanced four products to market approval and has out-licensed four innovative drug candidates.

The company's core asset, 9MW2821, is the second globally approved Nectin-4 targeted ADC for urothelial carcinoma and the first worldwide to enter pivotal Phase III clinical trials for cervical cancer and triple-negative breast cancer indications. Three Phase III clinical trials are expected to undergo interim analysis in the second half of this year. Based on the results, the company plans to submit a pre-NDA meeting request to the Center for Drug Evaluation (CDE).

Notably, MABWELL-B announced that it will present two latest clinical study results for its Nectin-4 targeted ADC innovative drug, 9MW2821, in cervical cancer at the 2026 European Society for Medical Oncology Gynecological Cancers (ESMO GC) Congress. The presentations will take place in Copenhagen, Denmark, from June 17–19, 2026, in both oral and poster formats.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162663926?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 11:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162663926","market":"sg","top_or_hot":-1,"title":"MABWELL-B Shares Surge Over 23% to Record High in Early Trading, Four Products Approved for Market","media":"Deep News","content":"<p>MABWELL-B (02493) saw its shares rise more than 23% during early trading, reaching a peak of HK$31.46, marking a new record high since its listing. At the time of writing, the stock was up 7.22% to HK$27.32, with a turnover of HK$184 million.</p>\n<p>On April 28, MABWELL-B officially began trading on the main board of the Hong Kong Stock Exchange and was included in the Stock Connect scheme on its first day, becoming the first A-to-H share company listed under Chapter 18A. Since its establishment, the company has successfully advanced four products to market approval and has out-licensed four innovative drug candidates.</p>\n<p>The company's core asset, 9MW2821, is the second globally approved Nectin-4 targeted ADC for urothelial carcinoma and the first worldwide to enter pivotal Phase III clinical trials for cervical cancer and triple-negative breast cancer indications. Three Phase III clinical trials are expected to undergo interim analysis in the second half of this year. Based on the results, the company plans to submit a pre-NDA meeting request to the Center for Drug Evaluation (CDE).</p>\n<p>Notably, MABWELL-B announced that it will present two latest clinical study results for its Nectin-4 targeted ADC innovative drug, 9MW2821, in cervical cancer at the 2026 European Society for Medical Oncology Gynecological Cancers (ESMO GC) Congress. The presentations will take place in Copenhagen, Denmark, from June 17–19, 2026, in both oral and poster formats.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MABWELL-B Shares Surge Over 23% to Record High in Early Trading, Four Products Approved for Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMABWELL-B Shares Surge Over 23% to Record High in Early Trading, Four Products Approved for Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-04-30 11:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MABWELL-B (02493) saw its shares rise more than 23% during early trading, reaching a peak of HK$31.46, marking a new record high since its listing. At the time of writing, the stock was up 7.22% to HK$27.32, with a turnover of HK$184 million.</p>\n<p>On April 28, MABWELL-B officially began trading on the main board of the Hong Kong Stock Exchange and was included in the Stock Connect scheme on its first day, becoming the first A-to-H share company listed under Chapter 18A. Since its establishment, the company has successfully advanced four products to market approval and has out-licensed four innovative drug candidates.</p>\n<p>The company's core asset, 9MW2821, is the second globally approved Nectin-4 targeted ADC for urothelial carcinoma and the first worldwide to enter pivotal Phase III clinical trials for cervical cancer and triple-negative breast cancer indications. Three Phase III clinical trials are expected to undergo interim analysis in the second half of this year. Based on the results, the company plans to submit a pre-NDA meeting request to the Center for Drug Evaluation (CDE).</p>\n<p>Notably, MABWELL-B announced that it will present two latest clinical study results for its Nectin-4 targeted ADC innovative drug, 9MW2821, in cervical cancer at the 2026 European Society for Medical Oncology Gynecological Cancers (ESMO GC) Congress. The presentations will take place in Copenhagen, Denmark, from June 17–19, 2026, in both oral and poster formats.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1162663926","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162663926","pubTimestamp":1777520462,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"MABWELL-B (02493) saw its shares rise more than 23% during early trading, reaching a peak of HK$31.46, marking a new record high since its listing. At the time of writing, the stock was up 7.22% to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688062":"迈威生物","BK0239":"医药制造","BK1161":"生物科技","02493":"迈威生物-B","IPOS":"Renaissance International IPO ETF"},"translate_title":"MABWELL-B股早盘大涨超23%创历史新高四款产品获批上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688062":1,"IPOS":1,"02493":1},"content_text":"MABWELL-B (02493) saw its shares rise more than 23% during early trading, reaching a peak of HK$31.46, marking a new record high since its listing. At the time of writing, the stock was up 7.22% to HK$27.32, with a turnover of HK$184 million.\nOn April 28, MABWELL-B officially began trading on the main board of the Hong Kong Stock Exchange and was included in the Stock Connect scheme on its first day, becoming the first A-to-H share company listed under Chapter 18A. Since its establishment, the company has successfully advanced four products to market approval and has out-licensed four innovative drug candidates.\nThe company's core asset, 9MW2821, is the second globally approved Nectin-4 targeted ADC for urothelial carcinoma and the first worldwide to enter pivotal Phase III clinical trials for cervical cancer and triple-negative breast cancer indications. Three Phase III clinical trials are expected to undergo interim analysis in the second half of this year. Based on the results, the company plans to submit a pre-NDA meeting request to the Center for Drug Evaluation (CDE).\nNotably, MABWELL-B announced that it will present two latest clinical study results for its Nectin-4 targeted ADC innovative drug, 9MW2821, in cervical cancer at the 2026 European Society for Medical Oncology Gynecological Cancers (ESMO GC) Congress. The presentations will take place in Copenhagen, Denmark, from June 17–19, 2026, in both oral and poster formats.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162663926","isCrawlerRequest":true}